The FDA has notified healthcare professionals that it is requiring the manufacturers of licensed botulinum toxin products, including Botox and Botox Cosmetic (botulinum toxin type A, from Allergan) ...

MALVERN, PA - May 1 - Myobloc(R) (Botulinum Toxin Type B) Injectable Solution, marketed by Solstice Neurosciences Inc., has received coverage equivalent to that of Allergan's BOTOX(R) (Botulinum Toxin ...

Early Communication about an Ongoing Safety Review Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) This information reflects FDA’s current analysis of ...

Health Canada, the federal agency, has announced it is reviewing the safety of the wrinkle treatment Botox and of a similar drug called Myobloc. The move comes only days after a call from a U.S. lobby ...

LOUISVILLE, Ky., Aug. 26, 2019 /PRNewswire/ -- US WorldMeds, LLC announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for ...

Elan has sold its worldwide rights to Myobloc, a drug treatment for chronic back and neck pain. Myobloc was developed by Elan and is currently approved in the US, Canada and Europe for the treatment ...

ISEQ-listed Elan Corporation today announced that it has completed the sale of its worldwide rights to Myobloc/Neurobloc injectable solution to Solstice Neurosciences a newly-formed company focused on ...